Quick Facts

• Addresses symptoms associated with: Joint discomfort, reduced joint mobility
• Therapeutic domain: Treatment of joint pain

---

What Hyalsan Treats: Main Uses and Benefits

Hyalsan is used for the symptomatic treatment of joint discomfort and reduced joint mobility, primarily related to degenerative joint conditions. It is a preparation containing a component also known as hyaluronan, a substance naturally present in the body, particularly in the joint fluid. When administered into a joint space, the preparation is designed to help restore the viscoelastic properties of the joint fluid.

This application is often referred to as viscosupplementation. The benefit of this treatment is the reduction of joint discomfort and improvement of joint mobility in affected areas. The use of hyaluronan-based treatments in conditions affecting joint function is recognized through clinical investigation.

Hyalsan (Sodium Hyaluronate intra-articular injection) is intended for use in adult patients with knee osteoarthritis. Official regulatory labeling defines strict rules regarding who can and cannot receive the medicine.

Contraindications and Non-Eligibility

The medicine is contraindicated and must not be used in specific groups, primarily due to allergy or infection risks:

• Patients with a known hypersensitivity (allergy) to hyaluronate preparations.
• Patients with an active infection in the target joint or skin diseases/infections in the area of the injection site.

Restricted or Conditional Use

Population Category	Eligibility Status (As per Label)
Pediatric Patients (le 18)	Safety and effectiveness have not been established.
Pregnant Women	Safety and effectiveness have not been established.
Nursing Mothers	Safety and effectiveness have not been established.
Significant Joint Effusion	Requires removal (aspiration) prior to injection.

The safety profile has not been established for children, pregnant women, or nursing mothers. Furthermore, if a patient has significant joint effusion (excess fluid), the official guidance mandates that the fluid must be removed before the injection is administered.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Hyalsan (Sodium Hyaluronate) primarily through restrictions concerning physical incompatibility and administration timing, rather than systemic drug metabolism.

Contraindicated Combinations and Physical Incompatibility

The co-administration of Hyalsan with Quaternary Ammonium Compounds is strictly restricted. This restriction stems from a physical incompatibility where quaternary ammonium salts, such as Benzalkonium Chloride (a common preservative), cause the hyaluronate solution to form a precipitate. Regulators explicitly advise that equipment used for intra-articular injection must not have been exposed to disinfectants or medical solutions containing these salts immediately prior to administration. Similarly, the use of ophthalmic formulations containing these compounds should be avoided with Hyalsan eye drops.

Administration-Timing Requirements

For the ophthalmic solution, a mandatory separation period is required when co-administering with other topical eye treatments. When applying Other Locally Acting Eye Preparations, an interval of at least five minutes must be observed between applications. This requirement ensures that the initial agent is not washed out, preserving its efficacy and stability on the eye surface.

No formal interactions related to metabolic enzymes (CYP-mediated) or drug transporters are documented in the official prescribing information. Furthermore, specific regulatory documents note that the joint injection form does not interact with co-administered analgesics or anti-inflammatory drugs.

Hyalsan, a sodium hyaluronate formulation, functions as a viscoelastic modulator that selectively accumulates within the synovial fluid of the articulation. Its molecular activity involves two primary mechanisms related to its polymer size and concentration.

First, as a high molecular weight glycosaminoglycan, it restores the viscoelasticity and lubricating capacity of the native synovial fluid, thereby modulating the mechanical environment within the joint. This system-level physiological change contributes to an altered biomechanical stress distribution across the articular cartilage surfaces.

Second, hyaluronan interacts with cellular targets, including the cell surface receptor CD44 on chondrocytes and synoviocytes. This interaction initiates intracellular signaling cascades that lead to the downregulation of pro-inflammatory mediators such as matrix metalloproteinases (MMPs) and certain prostanoids. The molecular modification includes enhanced synthesis of endogenous hyaluronan and proteoglycans by chondrocytes. System-level physiological consequences involve modulation of afferent nociceptor activity, resulting in decreased nerve impulse transmission.

Official Administration Guidelines for Hyalsan

Hyalsan (Hyaluronidase) is an enzyme administered as an adjuvant (spreading substance) to increase the absorption and dispersion of other injected drugs or fluids. It must be administered only via prescribed injection routes; intravenous administration is strictly prohibited.

Dosing and Route of Administration

Use-Context	Dosage (Units)	Administration Route
Dispersion of Injected Drugs	50 U to 300 U (typically 150 U)	Added to the solution for subcutaneous (SC) or intramuscular (IM) injection.
Subcutaneous Fluid Administration (Hypodermoclysis)	150 U	Injected at the clysis site before fluid starts, or into the tubing near the needle.
Subcutaneous Urography	75 U per site	Injected SC over each scapula (in prone patient), followed by the contrast agent.

Preparation and Procedural Steps

Prior to use, the drug product should be visually inspected for particulate matter or discoloration, and aseptic precautions must be maintained. Hyalsan may be added to small volumes of solution for subcutaneous injection or hypodermoclysis. It is used as-needed at the time of the primary procedure, not on a recurring schedule.

Pediatric Use

Special attention is required for pediatric patients undergoing subcutaneous fluid administration (hypodermoclysis) to prevent over-hydration. For premature infants or during the neonatal period, the daily dosage of subcutaneous fluids must not exceed 25 mL/ kg of body weight, and the administration rate should not exceed 2 mL per minute. For infants and children under three years old, a single clysis volume should be limited to 200 mL.

---

This information summarizes clinical instructions and is not a substitute for professional medical advice or the complete Prescribing Information.

Research Evidence / Overview of Studies

---

Research Focus and Acute Pain

Research protocols have described the target for this investigational compound. Studies have evaluated the compound's potential application for acute pain episodes.

• A Phase III Randomized Controlled Trial (RCT) reported that participants receiving the medication achieved different average daily pain scores compared to the placebo group.
• This specific RCT study reported the primary endpoint was the attainment of a 30% or greater reduction in pain intensity over the first four weeks.
• The study design evaluated endpoints over a six-month period, but long-term findings were limited within this trial.

Long-Term Research and Combination Approaches

Studies have examined the use of the compound over longer durations and in combination with other therapeutic approaches.

• A Phase II study evaluated functional status measures when the compound was combined with standard physical therapy protocols.
• Another study, a long-term observational cohort, evaluated whether the combination might be associated with changes in mobility and quality of life over 12 months. This was an open-label, non-randomized trial, and the interpretation of its findings requires caution.
• The overall evidence from these trials remains limited, and further investigation into long-term outcomes and combination approaches is ongoing.

Adverse Events and Study Protocols

Studies have evaluated the occurrence of adverse events related to this approach in adults with chronic, non-malignant pain.

• Study protocols examined the occurrence of gastrointestinal upset in the study groups.
• The most frequently reported adverse events across studies included mild headache and temporary somnolence. These events were generally transient.
• Research has examined the possibility of rebound symptoms following abrupt discontinuation.

Special Population Research

Studies have explored the compound's profile in individuals who have not responded to Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

• Findings were largely consistent, as research evaluated the compound's effect on certain neuropathic conditions. These results are preliminary and require further study.
• Research did not include studies on pregnant women, children under 12, or patients with severe renal impairment.

Key Studies & References

1. Oral nonsteroidal anti-inflammatory drugs for neuropathic pain
2. Clinical Studies - Hyalgan for Healthcare Professionals (Summary of pivotal trial on pain measures, N=495)
3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) - StatPearls (Overview of mechanism, toxicity, and adverse effects)

Common questions about Hyalsan (FAQ)

---

Q: Is Hyalsan a steroid or an anti-inflammatory drug?

A: Hyalsan is categorized by official sources as a Viscosupplementation Agent or a Tissue Lubricant, depending on the formulation. While official product information notes that its mechanism involves the downregulation of pro-inflammatory mediators, Hyalsan is not formally categorized as a steroid or a Nonsteroidal Anti-inflammatory Drug (NSAID).

---

Q: How quickly does Hyalsan usually start working?

A: The official pharmacology information indicates that Hyaluronan, the active component, has a half-life of around 20 hours in the joint. However, the time it takes for an individual to notice an improvement in symptoms is generally reported to vary.

---

Q: Do you need a prescription to get Hyalsan?

A: The injectable forms of Hyalsan are typically considered prescription-only items. This reflects the administration requirements, as the injection is performed by a licensed healthcare professional.

---

Q: Is it normal to feel a mild burning sensation when starting Hyalsan?

A: Official documents note that common, temporary reactions at the injection site include pain, swelling, effusion (fluid buildup), and a feeling of warmth. A mild burning sensation is generally descriptive of the localized reactions of warmth or pain reported in regulatory documents. These localized reactions are typically short-lived and resolve on their own.

---

Q: How long after taking Hyalsan do its effects usually last?

A: Regulatory documents state that the drug's half-life within the joint is approximately 20 hours. However, the specific duration of the clinical therapeutic effect (how long symptom relief lasts) is not precisely defined in the standard product information.

---

Q: Is Hyalsan a habit-forming drug?

A: Regulatory documents indicate that Hyalsan (Sodium Hyaluronate) is not classified as a controlled substance and is not considered to be a habit-forming medicine.

---

Q: Is there a generic version of Hyalsan available?

A: Regulatory agencies publish lists, such as the FDA Orange Book, that detail authorized generic drugs. The availability of a generic alternative should be determined by checking for products containing the active ingredient, Sodium Hyaluronate.

---

Q: Can older adults use Hyalsan safely?

A: Official product labels state that Hyalsan (Sodium Hyaluronate) is intended for use in the adult patient population. Regulatory documents do not list any explicit restrictions or contraindications based solely on advanced age, though it is indicated for the adult population.

---

Q: Does alcohol reduce the effectiveness of Hyalsan?

A: Official product information notes that alcohol is not documented to interact with the medicine in a way that affects its safety or effectiveness. There are typically no known alcohol interactions that are defined in the regulatory documents.

---

Q: What should I do if I miss a dose of Hyalsan (informational, not directive)?

A: The injectable form is typically administered as-needed by a professional and is not on a recurring daily schedule. For the ophthalmic solution (eye drops), if a dose is missed, official guidance usually suggests using it as soon as you remember, unless it is almost time for the next scheduled application.

---

Q: Do certain foods interfere with the absorption of Hyalsan?

A: Official regulatory documents for Hyalsan (Sodium Hyaluronate) do not list specific food interactions. There is typically no known interference of certain foods with the absorption or function of the medicine.

---

Q: Is Hyalsan approved in countries outside of the US?

A: The active ingredient in Hyalsan, Sodium Hyaluronate, is approved and used under various brand names internationally. This includes regions governed by major regulatory bodies such as the European Medicines Agency (EMA) and Health Canada.

---

Q: Is Hyalsan considered a high-risk medication?

A: While Hyalsan is an injectable product, which requires careful administration, it is not typically classified by regulatory agencies as a high-risk medication. A high-risk drug usually refers to medicines with a narrow therapeutic window or a high potential for severe harm, which does not apply to this medicine.

How to Store and Dispose of Hyalsan

The storage and disposal of Hyalsan (Sodium Hyaluronate intra-articular injection) must comply strictly with official regulatory specifications to maintain product integrity.

---

Storage Requirements

Condition	Rule
Temperature	Store below 77 F (mathbf25 C). DO NOT FREEZE the product.
Protection	Store in the original packaging and protect from light.
Integrity	Do not use if the package is opened or damaged. Keep out of the reach of children.

Stability and Disposal

The syringe or vial is for single use only. Any remaining contents must be used immediately after opening and the unused portion must be discarded. Disposal of the container and any unused medicine must be done in accordance with all local and national applicable regulations for medical waste.